Results 61 to 70 of about 23,011 (205)

Integrated Engineering of CAR‐T Cells for Solid Tumours

Cell Proliferation, EarlyView.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang, Tan Li, Ping He, Zhijie Zhao, Shenglong Li, Liming Wang   +5 more
wiley   +1 more source

Superficial Ewing Sarcoma of the Rectum: A Case Report and the Utility of Molecular Diagnostics

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Ewing sarcoma is an undifferentiated small round cell sarcoma that most commonly presents as a malignant bone tumor in pediatric and young adult patients. The diagnosis is typically confirmed by molecular genetic identification of a fusion protein, most commonly involving members of the FET and ETS gene families.
Jessica L. Muldoon, Laura M. Warmke, Ahmed K. Alomari, Rachel P. Kowal   +3 more
wiley   +1 more source

A Recurrent Indurated Plaque on the Thigh

JEADV Clinical Practice, EarlyView.
Tram T. Tran, Sabine L. Abukhadra, Samuel T. Hwang, Maija Kiuru   +3 more
wiley   +1 more source

Primary Cutaneous Gamma‐Delta T‐Cell Lymphoma Complicating Long‐Standing Immunosuppressed Dermatomyositis

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Primary cutaneous gamma‐delta T‐cell lymphoma (PCGD‐TCL) is a rare cytotoxic lymphoma with key oncogenic drivers in the JAK/STAT pathway. Also primarily involving the subcutaneous adipose tissue, subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL) is more frequently encountered in scenarios of autoimmune disorders.
Bennett Christie‐Nguyen, Youn H. Kim, David F. Fiorentino, Danielle Tartar, Ryanne Brown, Robert A. Novoa, Kerri E. Rieger   +6 more
wiley   +1 more source

Rejection resistant CD30.CAR-modified Epstein-Barr virus-specific T cells as an off-the-shelf platform for CD30+ lymphoma

Molecular Therapy: Oncology
Off-the-shelf (OTS) adoptive T cell therapies have many benefits such as immediate availability, improved access and reduced cost, but face the major challenges of graft-vs-host disease (GVHD) and graft rejection, mediated by alloreactive T cells present
David H. Quach, Haran R. Ganesh, Yolanda D. Briones, Nazila Nouraee, Audrey Ma, Yezan F. Hadidi, Sandhya Sharma, Cliona M. Rooney   +7 more
doaj   +1 more source

The Inverse Koebner Phenomenon in Cutaneous T‐Cell Lymphomas

JEADV Clinical Practice, EarlyView.
Alba Guglielmo, Corrado Zengarini, Alessandro Borghi, Alessandro Pileri   +3 more
wiley   +1 more source

Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Chronic pruritus (CP) and chronic prurigo (CPG, including prurigo nodularis) are prevalent, debilitating diseases with diverse comorbidities, including malignancies. This retrospective cohort study evaluated the prevalence and risk of lymphoma in CP and CPG patients, including key risk factors, and sex‐ and ancestry ...
Svenja Royeck, Henning Olbrich, Steffen Koschmieder, Claudia Zeidler, Felix Witte, Konstantin Agelopoulos, Henning Wiegmann, Michael Storck, Johannes Benedict Oehm, Ralf J. Ludwig, Sonja Ständer   +10 more
wiley   +1 more source

A Response to “The Inverse Koebner Phenomenon in Cutaneous T‐Cell Lymphomas”

JEADV Clinical Practice, EarlyView.
Isabel Hariri, Alexander H. Enk, Jessica C. Hassel   +2 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

CD30: seeing is not always believing [PDF]

Blood, 2015
Although most investigators are well aware of the incredible success of brentuximab vedotin in the treatment of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jacobsen and colleagues in this issue of Blood demonstrates surprising activity of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).
openaire   +2 more sources